National study of COVID-19 Natural Immunity in Unvaccinated Persons
Below you will find information about this study titled:
The National Study of COVID-19 Natural Immunity in Unvaccinated Persons (IRB00295352) is being led by a research team of surgeons, infectious disease doctors and epidemiologists at Johns Hopkins. The principal investigator is Dorry Segev, MD PhD, Associate Vice Chair of Surgery at Johns Hopkins. Dr. Segev’s research uses advanced statistical methods for mathematical modeling and simulation of medical data, analysis of large healthcare datasets, and outcomes research. Dr. Segev has partnered with Marty Makary, MD MPH, Chief of the Johns Hopkins Islet Transplant Center. Dr. Makary’s research focuses on the creation and evaluation of new health care innovations. He is also a leading voice for physicians, writing in The Wall Street Journal, and is the author of The New York Times best-selling book Unaccountable.
The purpose of this study is to determine COVID-19 antibody levels in people who have not had a COVID vaccine. The study does not provide the vaccine and study team members will not be offering guidance or medical advice as to whether or not one should receive a SARS-CoV-2 vaccine. If participants are interested in the study, they will be asked to complete a brief questionnaire and provide a blood sample which will be tested for antibodies. The study team will share the results with the participants if they wish.
Thank you for your interest in our study of natural immunity to COVID-19 in unvaccinated persons. Due to an overwhelming interest in our study, we have reached capacity and have closed enrollment at this time.
Due to an overwhelming interest in our study, we have reached capacity and temporarily suspended new enrollment.
If you previously completed our enrollment questionnaire, please check the email that you provided. If you screened into active eligibility, you will have received an email from email@example.com with instructions on how to complete antibody testing. Not everyone who completed the enrollment questionnaire is eligible for antibody testing. At this time, everyone who screened into active eligibility has received this email. We will send out one final reminder to those who have screened into antibody testing the week of 10/25/2021.
For more information, you may email our study team at firstname.lastname@example.org.
Dorry Segev, MD, PhD | Martin Makary, MD, MPH | Robin Avery, MD | William Werbel, MD | Jonathan Mitchell, MBBS | Jennifer Alejo, MD